A Phase 3, Dose-Optimized, Double-Blind, Randomized, Placebo-Controlled, Parallel Efficacy and Safety Laboratory Classroom Study in Children (6-12) With Attention-Deficit/Hyperactivity Disorder (ADHD) Using CTx-1301 (Dexmethylphenidate)
Latest Information Update: 26 May 2026
At a glance
- Drugs Dexmethylphenidate (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Registrational; Therapeutic Use
- Sponsors Cingulate Therapeutics
Most Recent Events
- 05 May 2026 Planned End Date changed from 1 Mar 2026 to 1 Feb 2027.
- 05 May 2026 Planned primary completion date changed from 1 Mar 2026 to 1 Feb 2027.
- 14 Aug 2025 Planned End Date changed from 1 Aug 2026 to 1 Mar 2026.